FDA clears a brain-mapped TMS protocol for PTSD at Texas A&M and Wave Neuroscience

The US Food and Drug Administration has cleared a transcranial magnetic stimulation system that uses a recording of a patient's brain activity to set the treatment map for post-traumatic stress disorder. Wave Neuroscience built the platform with Kenneth S. Ramos's group at the Texas A&M Health Institute of Biosciences and Technology. The clearance was described in a university release dated 28 August.

TMS already has an FDA label for treatment-resistant depression. A coil on the scalp delivers magnetic pulses that change firing patterns in targeted cortex. The new clearance adds an algorithm that reads an electroencephalogram and writes a protocol the company brands as magnetic e-resonance therapy, or MeRT. Erik Won, who has worked on the commercial side of the method, said the extra mapping step should open the device to about 13 million people who meet criteria for PTSD.

Israel Liberzon, the lead psychiatrist on the supporting study, said that once clinics offer the system it will be the only cleared non-medication treatment with a PTSD-specific label. The FDA has approved two drugs for the condition. Talk therapies such as prolonged exposure and cognitive processing therapy remain first-line in most guidelines. They are not devices and do not go through the same clearance route.

What the label does and does not say

Clearance is not the same as a large outcomes trial published in a major journal. The university note stresses personalisation and an objective map. It does not publish a remission rate, a dropout rate or a comparison against sham stimulation in the release that circulated on 28 August. Clinics that buy the system will still need a physician to order the map and to watch for the known TMS risks: scalp pain, headache and, rarely, a seizure.

A separate company, Neurovalens, received a de novo classification earlier in the year for Modius Spero, a behind-the-ear headset that delivers 30-minute daily sessions at home. That device is being offered through the Department of Veterans Affairs. It is not the Texas A&M system. Readers who see two PTSD-device headlines in the same week are looking at two mechanisms: mapped TMS in a clinic, and a wearable neuromodulator used at home.

Veteran suicide remains the political frame both firms use. The Texas A&M note cites about 17.5 veteran suicides a day and a 7 percent annual PTSD diagnosis rate among veterans. Those figures describe the market. They do not measure the device. A veteran who has already failed sertraline or paroxetine, the two approved drugs, now has a cleared hardware option whose protocol is written from that person's own EEG.

The practical next step

Hospitals that already run TMS chairs for depression can add the mapping software if they buy the Wave package. That is a billing and training decision. Insurers have not said whether they will pay. The VA path used by Neurovalens is a different procurement track. For a patient the difference is concrete. One treatment is a clinic appointment with a coil. The other is a headset at the kitchen table. Neither replaces a clinician, and both still sit beside the two old pills and the two old talking cures.

The information gain in Friday's note is the label itself. PTSD now has a device clearance that names the diagnosis, uses an EEG to set the dose, and comes out of a Texas A&M collaboration rather than a psychiatry-only lab. How many people finish a course, and how many still meet diagnostic criteria six months later, is the measurement that the clearance does not yet provide.